Skip to main content

Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET

What Overall Survival Really Means

Improved overall survival is a promising result that some women with HR+, HER2- metastatic breast cancer (mBC) are seeing in clinical trials, so it's important to understand what exactly the term means. Watch the video below to learn about the significance of overall survival (OS) and progression-free survival (PFS)—2 very important terms with very different meanings.

There Is a Difference Between Progression-Free Survival and Overall Survival:
Icon PROGRESSION-FREE SURVIVAL (PFS)

PROGRESSION-FREE SURVIVAL (PFS)

The amount of time cancer doesn’t grow or spread while on treatment. It’s about putting cancer growth on pause.
 

OTHER WAYS TO DESCRIBE PFS

  • Amount of time disease progression is delayed

  • Living longer without your cancer getting worse

  • More time without disease progression

Icon OVERALL SURVIVAL (OS)

OVERALL SURVIVAL (OS)

The total time living with metastatic breast cancer. It’s about adding more days to a person’s life.
 

OTHER WAYS TO DESCRIBE OS

  • Living longer

  • More time to live

  • A chance to live longer

Overall survival is the gold standard in cancer clinical trials. Not all treatments have proven overall survival. KISQALI has—multiple times
Graph explaining overall survival. If life was a race, no one would want to reach the finish line. PFS would help by putting the race on pause for a while. OS would help by moving the finish line further away to make the race last longer.
KISQALI with hormone therapy is proven to both extend life and preserve or improve quality of life

Important Safety Information

What is the most important information I should know about KISQALI ?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...

Indications

KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:

  • an aromatase inhibitor as the first endocrine-based therapy; or...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE